← All trials
NCT06118034
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2024
- Primary completion
- Aug 31, 2026
- Completion date
- Dec 30, 2026
- First posted
- Nov 7, 2023
- Last posted
- Nov 7, 2023
- Enrollment
- 768
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing UniversityLead sponsor
- Harbin Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Jinan UniversityCollaborator
- Nanjing UniversityOverall official - principal investigator
- Nanjing UniversityStudy chair
- Nanjing UniversityStudy director
- The First People's Hospital of ChangzhouCollaborator
- Yangzhou UniversityCollaborator
- Nanjing UniversityOfficial
- Shihezi University Medical CollegeCollaborator
- Shandong Provincial HospitalCollaborator
- Nantong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.